JAZZJazz PharmaceuticalsSigning up patients
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
HER2-positive Breast Cancer · Breast Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 125 (planned)
- Started
- Sep 24, 2025
- Main results expected
- Dec 29, 2027
- Fully finished
- May 2, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with pCR
Measured over: Up to 8 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07102381 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC